{"links":{"feed":"https://www.erudio.com/reports/gdfather-neo-nct06059547/feed.json","html":"https://www.erudio.com/reports/gdfather-neo-nct06059547","json":"https://www.erudio.com/reports/gdfather-neo-nct06059547.json","markdown":"https://www.erudio.com/reports/gdfather-neo-nct06059547.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"gdfather-neo-nct06059547"}},"request":"https://www.erudio.com/contact?report=gdfather-neo-nct06059547"},"offer":{"cited_clinicians":10,"cited_commentary_sources":39,"verified_hcp_statements":112,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":14},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"gdfather-neo-nct06059547"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=gdfather-neo-nct06059547","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/gdfather-neo-nct06059547","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 112 verified statements · 29 from 10 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-18T07:39:02.091075Z","notify_subscribers":true,"status":"updated","summary":"Replaces version 1.0.0: 8 findings, 2 of them beyond the trial population (was 8, 2 of them), 112 verified statements (was 112) from 40 sources (was 40)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":28,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":26,"title":"Primary endpoint: Pathological complete response rate"},{"claim_count":20,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":19,"title":"Primary endpoint: Radiological response rate according RECIST"},{"claim_count":23,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":14,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":35,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":24,"title":"The comparison"},{"claim_count":24,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":20,"title":"Safety and tolerability"},{"claim_count":17,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":15,"title":"Design and conduct"},{"claim_count":19,"coverage":"discussed","id":"A1","source_count":12,"title":"Response-conditioned bladder preservation and limits on changing surgery"},{"claim_count":20,"coverage":"discussed","id":"A2","source_count":10,"title":"Immune-resistance rationale and investigational biological selection"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":5,"title":"Neoadjuvant MIBC positioning amid evolving perioperative alternatives"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":7,"title":"Untested combinations and proposed de-escalation in deep responders"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":2,"title":"European clinical-research environment"},{"claim_count":11,"coverage":"discussed","id":"A6","source_count":7,"title":"Study novelty, evaluative reactions and wider GDF-15 visibility"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":9,"cited_clinicians":10,"cited_clinicians_by_role":{"physician":4,"physician, Medical oncology":6},"cited_physicians":10,"cited_sources":40,"claims_by_expression_type":{"comparison":10,"experience":2,"interpretation":33,"opinion":30,"primary_context":5,"question":3,"restatement":25,"uncertainty":1,"unspecified":3},"claims_by_kind":{"publication_statement":3,"source_observation":109},"clinician_statements":29,"evidence_units":56,"findings":8,"organisational_accounts":5,"people_cited":15,"people_identity_verified":14,"people_total":15,"screened_sources":70,"verified_claims":112},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":4},"limitations":2,"links":{"context":1,"support":7},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Cystectomy omission: why a clinician sees proof of concept as insufficient","title_holders":{"cited_claim_ids":["claim-d3cd6aa2318642abd016"],"clinicians":true,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"7 statements from 3 speakers in 4 sources, 1 of them a podcast or video","holder_line":"1 of the 3 named speakers in this finding holds this view, a confirmed clinician"},{"cited_clinicians":2,"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":4},"limitations":2,"links":{"context":2,"support":12},"ma_question":true,"named_voices":5,"passages":8,"sources":8,"sources_by_kind":{"commentary":2,"media":5,"publication":1}},"title":"Response gap: most speakers limit inference; a clinician questions control responses","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-43c3ac065815fbeb2623","claim-c4e890fd7c47ee05aff8"],"clause":"a clinician questions control responses","holders":1},"cited_claim_ids":["claim-bc2b1ac6794fd5dd257e","claim-bba264fdf9385bfd273e","claim-8f4cd7c7679ce523af84"],"clinicians":false,"holders":3,"speakers":5,"view":"reading"},"evidence_line":"10 statements from 5 speakers in 8 sources, 5 of them podcasts or videos","holder_line":"3 of the 5 named speakers in this finding hold this view; 1 of the 5 holds its caveat, “a clinician questions control responses”"},{"cited_clinicians":6,"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":3,"views":9},"limitations":3,"links":{"context":2,"support":15},"ma_question":true,"named_voices":8,"passages":11,"sources":11,"sources_by_kind":{"commentary":8,"media":2,"publication":1}},"title":"GDFATHER-NEO: what most speakers highlight in the size of the response difference","title_holders":{"cited_claim_ids":["claim-f9f3d8315de7a23d6e40","claim-5d2a3c66f728ddd52d68","claim-d34f4edb89afc9f4f90c","claim-6167c6b1790790c8cc60","claim-40e5967002264a99f6ed","claim-7aadcbd69a7f6b81f2d1","claim-43c3ac065815fbeb2623","claim-c4e890fd7c47ee05aff8"],"clinicians":false,"holders":7,"speakers":8,"view":"reading"},"evidence_line":"14 statements from 8 speakers in 11 sources, 2 of them podcasts or videos","holder_line":"7 of the 8 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":4,"passages":7,"sources":6,"sources_by_kind":{"commentary":3,"media":2,"publication":1}},"title":"Curative care: speakers note tolerability; one seeks no added toxicity","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-5b54560b70a315324b71"],"clause":"one seeks no added toxicity","holders":1},"cited_claim_ids":["claim-f5487d4eb12200997393","claim-5d2a3c66f728ddd52d68","claim-e1d5684c98f7505b2622","claim-d5c0e5886fad1277be1e"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"7 statements from 4 speakers in 6 sources, 2 of them podcasts or videos","holder_line":"4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “one seeks no added toxicity”"},{"cited_clinicians":1,"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":6},"limitations":2,"links":{"context":1,"support":9},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"GDF-15 blockade: why a clinician would test biology-guided, less invasive treatment","evidence_line":"9 statements from 4 speakers in 5 sources, 3 of them podcasts or videos"},{"cited_clinicians":1,"id":"F6","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":3},"limitations":4,"links":{"context":3,"support":6},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"MIBC care: a speaker sees possible shifts; a clinician expects better results","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-fdf17da3da61dfb2a051"],"clause":"a clinician expects better results","holders":1},"cited_claim_ids":["claim-5e7edd6417a1ad5feff2","claim-89250bacbf969f232868"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"6 statements from 3 speakers in 4 sources","holder_line":"1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician expects better results”"},{"cited_clinicians":0,"id":"F7","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":7},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":7,"sources":7,"sources_by_kind":{"commentary":5,"media":2}},"title":"GDF-15 combinations: how a speaker envisions de-escalation in deep responders","title_holders":{"cited_claim_ids":["claim-d8479826b22d9a17ccbd","claim-27c593329be304193692"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 7 sources, 2 of them podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":1,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"European clinical research: why a speaker calls for urgent changes","title_holders":{"cited_claim_ids":["claim-73f3e8cb008ffc4ea68a","claim-4c41593db59f1c89f04a"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From finding F1 (7 statements from 3 speakers in 4 sources)","cited_claim_ids":["claim-4770d2562f7f6a6d8e95","claim-df50412aeb4580d1de3d","claim-bcd7caa843fd91a17fb3","claim-d3cd6aa2318642abd016","claim-76179134085c14cfe0b5","claim-e159feb449e38f365e7b","claim-1da2b2aab6e31d5a5b82"],"finding_ids":["F1"],"question":"What do clinicians say larger prospective trials with longer follow-up must establish about event-free survival and bladder preservation before considering cystectomy omission after neoadjuvant visugromab plus nivolumab in muscle-invasive bladder cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One clinician calls the findings proof-of-concept, not grounds to omit cystectomy"},{"id":"section-2","level":2,"title":"One speaker questions the control response; one interview limits arm-to-arm interpretation"},{"id":"section-3","level":2,"title":"Accounts welcome the response signal and express enthusiasm for a new approach"},{"id":"section-4","level":2,"title":"Accounts welcome tolerability; one episode stresses avoiding added toxicity in a curative setting"},{"id":"section-5","level":2,"title":"One clinician asks whether GDF-15 blockade could support biologically selected, less invasive treatment"},{"id":"section-6","level":2,"title":"One presentation account anticipated shifting standards; one X account expected better forthcoming results"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"Could untested GDF-15 combinations support surgical and adjuvant de-escalation?"},{"id":"section-9","level":3,"title":"One trial-linked account calls for urgent changes in European clinical research"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Pathological complete response rate"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1}],"id":"T2","label":"Primary endpoint: Radiological response rate according RECIST"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":9},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":6}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-18T07:39:02.091075Z","edition_number":2,"previous_run_id":"3bd74643-8d72-4769-bf83-46418517fd73","previous_version":"1.0.0","product_contract":"hcp-commentary-1","published_at":"2026-11-18T07:58:14Z","record_hash":"94ee662f6da78af81424b7c06a8af2ec6498d06b168cdb8bef2732002eb8fb7f","release_hash":"c177f4922bb1964feb5b89d1939380fc79c95ec36f5bd62b19794815b9d06a15","report_id":"erudio-nct06059547","run_id":"73600c17-b171-4f4d-b449-6a6d6814379d","schema_version":"5.0","slug":"gdfather-neo-nct06059547","version":"1.1.0","version_reason":"material_change"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"One physician reads GDFATHER-NEO as warranting further investigation, not routine cystectomy avoidance, because pathological response need not translate into survival benefit. A speaker emphasizes response gains and describes tolerability favorably. Another physician questions the low nivolumab activity while cautioning against cross-trial comparisons. Recurrence-free observations concern only pathological complete responders, leaving durable bladder preservation uncertain.","examples":[],"meta_description":"70 sources screened · 112 verified statements (29 from clinicians verified by NPI or staff page) from 40 sources · 8 findings. Updated Nov 18, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-18T07:58:14Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":70},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on integrating circulating and urinary tumour DNA to predict response and recurrence after neoadjuvant bladder cancer therapy; a view on ctDNA and utDNA for predicting pathological response and recurrence-free survival after neoadjuvant treatment in muscle-invasive bladder cancer.","45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 6 sources about other trials or topics are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational accounts, congratulatory reactions, relays and repeated versions of discussions should not be counted as independent clinician endorsements.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The publication describes nonrandomized allocation, whereas some interview accounts say randomized. Response labels, major-response rates and control percentages also vary between accounts; these differences prevent a single harmonized rendering of what everyone reported.","Favorable recurrence follow-up is restricted to response-defined subgroups and remains short. It does not establish a whole-population survival advantage or the long-term safety of bladder preservation.","Coverage concentrated on trial names and identifiers. Relevant discussion using unnamed references, variant spellings or different transcription may be absent.","No trial protocol or exact regulatory label for visugromab was available among the sources reviewed. This limits detailed assessment of methods and regulatory positioning; it does not establish the drug's regulatory status.","Expectations about later presentations or readouts are preserved at the timing stated in the sources and are not evidence of what those later studies showed."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":6,"other":0,"podcast":1,"publication":1,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":39,"context":1},"count":40,"evidence_window":{"end":"2026-11-09","start":"2025-09-23"},"retrieval_snapshot":"2026-11-17T23:59:39.917203Z","timeline":[{"count":1,"week":"2025-W39"},{"count":11,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":2,"week":"2025-W49"},{"count":1,"week":"2026-W20"},{"count":3,"week":"2026-W28"},{"count":13,"week":"2026-W43"},{"count":4,"week":"2026-W44"},{"count":1,"week":"2026-W46"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT06059547:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06059547:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42926233","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-lc6hdhnjkgccd6ysi7e23pll-3myqaixhjh723","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mlekpoidynvrynshajyohuak-3mysptzbozv26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-sxyumipv6p6yiedtmdlrcvzd-3mynmlth4mk2r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tw3hsl5webkeb6flocjlqcwl-3mzuxe7u47i2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3m3foa73wom2p","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7376169550998040576","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384942718872875008","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384954647091900416","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7386368546773078016","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7481635844374769664","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519693863247192064","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7521628765278564353","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:dd4109","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1751251748466184618:bfe53da4-c1a4-4db2-bc45-fe7f79ad9dde","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1751292767035154434:eed1d9c1-3611-40de-8d69-e6d45436d21a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867599960373362691:6752a9fb-102a-49a2-9be7-75a020993810","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970400842155999291:dd45194c-9d5f-48bf-980a-5be2f239c1d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971617210675458053:11a40012-115b-4f96-a628-cbff09e90a24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978821087568769030:b39e9f68-0b08-44dc-b5e6-6aa78b5c6882","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979094775253844142:87197ab9-7dbf-4443-955c-83b12b736191","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173448472535435:1d520c80-de17-49a8-acde-30b733057ac7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173695361789954:80cb8e47-843f-465e-8dd5-11d06eae696d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173804979925344:bc60d75e-e52f-45fb-876e-062b2afc7a03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979173849506746599:0040dcfb-8519-4ada-9bbb-99eb3d6d0b20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979174152503463965:a3932bd7-6977-46d9-8856-25ded5109827","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979174659758383607:6fa6140e-f213-40f0-b4ba-e6b1581170bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979175056883187801:912725e1-85a6-45b9-9d53-fd6e7d14dec8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979176218348904476:4173da07-8b8e-43e7-a067-87b302e6c4d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979177192019104092:f45f4698-4432-410f-8f40-4e972269f8ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979184086154408176:f1bc3983-5d6d-4d41-9a7c-3dfa1604bb4b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979184244082532431:67a1f8ff-b29b-4901-96ae-52a85a523e60","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979211348891316364:5cfb888f-dfd9-47bb-a4ae-2292a2eb2c73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979253155247321254:1d829d9d-a79b-4d6f-81a2-d02cee1ead2e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979276573271376174:7db94fcd-6047-4ef5-bfe1-75b58a41005b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979278588223299871:8b4489d8-bc69-436b-9c07-17fcb2037966","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979437476390539726:59b14ea8-2299-4f92-b668-7b455c22bbf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979448694693859727:117cd16e-e9d4-4439-884f-559b724c7ce3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979480071434821944:8217886b-200d-438f-a170-765cd3adc579","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982115270257741922:225adc8d-e95a-4048-947f-f72c611b9693","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986524003167605162:d583947f-4644-4ec5-b39b-54ab13bd08df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075867922388373721:a215bb72-e2a5-40bb-8558-7f7f503f2950","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075868841381396693:a8e1a68c-e14f-4f76-97e6-7e3bc1e07dae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103890142922416181:6d509ca5-fc21-44d5-ae82-45e90b1955e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107914813942735028:86a9e266-f5f0-4c8a-8ae7-b37a5f7484d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113915131327324326:f9617bc3-88e6-43ab-8620-50db221db931","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113925638646051281:e975e5a8-5082-48bc-ba88-dab501b44f5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113926672856813794:e04620d3-a7c3-4493-adf1-5294c45dfcbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113926911403434494:8de526eb-a9b3-42b8-bbea-80bb722cfe94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113929033356317104:48e23418-865d-480c-bdcb-f2e8491f460b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113933186262556735:28f3e489-8a65-4039-9576-7ce8e7c78e76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113938131942576351:3e32459f-94b3-4c70-8aad-7049293b5a12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113943399455772720:787aaed5-c06f-4981-a824-b23ba0e0b319","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113989136566677658:af3b5342-84ed-4663-8053-c7c29d88878b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114025497478746244:b9ea420c-db0a-4d1a-95b0-95651f22b77e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114049724827193487:237905f3-13ee-48af-b285-79f85b53d34b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114049764862132603:c8f6be95-9fe5-401a-b127-41ef608b3576","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114071858387513621:00b2a55a-2b84-41a4-bc77-fef5cef2d0ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114251582527394089:21499d2d-8c93-4105-bbd1-c16c9b784b3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114254602296041650:4d5a30d8-13a0-4331-ba00-63514493976f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114412945887158405:854437fa-6147-4257-87ff-45845d0b55b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114626776739483652:b415b406-67ee-40b3-bd2f-f681599c2d0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115352961203237075:e744c687-bc47-463d-ba87-4db527535a14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115860838208733342:bfa535da-c583-455d-b092-e61df83ace8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117215571385135456:ec0a6ade-3a32-474a-b192-390d698bd06e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117611785293328868:fef05302-8e53-4e39-ad4f-7c4563f2f1c4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LIUEYok9c_g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZIHWrJymYSE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_9MGIbUorSw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:crXLluLny1Y","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:s7FaE7MCPHQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":7,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":52,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":70},"count":70,"evidence_window":{"end":"2026-11-09","start":"2024-01-27"},"retrieval_snapshot":"2026-11-17T23:59:39.917203Z","timeline":[{"count":2,"week":"2024-W04"},{"count":1,"week":"2024-W50"},{"count":3,"week":"2025-W39"},{"count":23,"week":"2025-W42"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":2,"week":"2025-W49"},{"count":1,"week":"2026-W20"},{"count":3,"week":"2026-W28"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":19,"week":"2026-W43"},{"count":6,"week":"2026-W44"},{"count":2,"week":"2026-W45"},{"count":1,"week":"2026-W46"}],"undated_sources":2},"statements_by_channel":{"bluesky_thread":4,"linkedin_post":21,"other":0,"podcast":5,"publication":3,"registry":0,"regulatory":0,"x_thread":40,"x_video":0,"youtube":39}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"label":"ESMO Congress 2026","slug":"esmo26","sources":7}],"drugs":[{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"visugromab","slug":"visugromab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"},{"reason":"Unmapped registry condition: Adult Solid Tumor","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"GDFATHER-NEO","aliases":["GDFATHER-NEO","CTL-002-002","Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer"],"brief_title":"Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Bladder Cancer","Adult Solid Tumor"],"display_condition":"muscle-invasive bladder cancer","display_interventions":[["visugromab","nivolumab"]],"enrollment":{"count":31,"type":"ACTUAL"},"interventions":[{"name":"Nivolumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Visugromab (CTL-002)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06059547","official_title":"A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2025-10-16","type":"ACTUAL"},"primary_endpoints":[{"description":"Rate of participants with complete pathological responses after IMP treatment as determined by local pathologist review","measure":"Pathological complete response rate","timeFrame":"min. 4 months"},{"description":"Rate of participants with radiological responses according to RECIST 1.1 prior Radical Cystectomy/Re-TURBT as assessed by the Investigator/Radiologist","measure":"Radiological response rate according RECIST","timeFrame":"min. 4 months"}],"registered_date":{"date":"2023-09-28","type":"ACTUAL"},"registry_last_updated":"2026-08-19","registry_url":"https://clinicaltrials.gov/study/NCT06059547","short_name":"GDFATHER-NEO","short_name_basis":"canonical_name","sponsor":"CatalYm GmbH","start_date":{"date":"2023-09-06","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"CTL-002-002","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}